Table 1.

IL-16 inhibits HIV-1Ba-L replication in MDMs and MDDCs

Cell typea and donorReverse transcriptase level (cpm/50 μl) in cultures treated withb:
RPMI 1640IL-16MIP-1α
MDMs
 147,83413,499 (72)57,170 (−20)
 278,07528,165 (64)51,879 (33)
 337,8483,702 (90)38,837 (−3)
 446,8983,602 (92)26,635 (43)
 585,63621,859 (74)ND
 Mean ± SEM59,258 ± 9,46414,165 ± 4,882 (78 ± 5) [0.0012]43,630 ± 6,850 (13 ± 15) [0.3638]
MDDCs
 116,4833,738 (83)ND
 210,8220 (100)ND
 316,440354 (98)14,530 (13)
 434,5103,747 (89)18,250 (47)
 520,8713,386 (84)24,381 (−17)
 622,301976 (96)26,051 (−17)
 Mean ± SEM20,237 ± 3,2942,033 ± 724 (92 ± 3) [0.0016]20,803 ± 2,680 (6 ± 15) [0.6021]
  • a MDMs and MDDCs from healthy donors were infected in vitro with HIV-1Ba-L and then cultured in the absence (RPMI 1640) or the presence of IL-16 (1 μg/ml) or MIP-1α (0.2 μg/ml).

  • b Supernatants from infected cultures were harvested and assayed on days 12 to 15 postinfection. Numbers in parentheses are percent inhibition; numbers in brackets are P values calculated by Student’s t test for paired data. ND, not determined.